Chemotherapy with or without talniflumate for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding talniflumate to standard chemotherapy before surgery works better than chemotherapy alone for breast cancer. It's for women who have not yet had any anti-cancer drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with breast cancer through a biopsy.
- You have not taken any cancer drugs before this trial.
- Your liver and kidney function and blood counts are within safe ranges.
- You are expected to live at least 6 months.
- You sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.